Kardigan is a South San Francisco heart health company modernizing cardiovascular drug development. Founded by the team behind MyoKardia, it pairs a late-stage clinical pipeline in dilated cardiomyopathy, acute severe hypertension and calcific aortic valve stenosis with a 'cardiac intelligence' platform - real-world patient data and AI - to match disease drivers to the right responders.
Tassos Gianakakos is a Greek-American biotech entrepreneur and the co-founder, CEO, and Chair of Kardigan, a cardiovascular drug discovery company he built from the ashes of MyoKardia — the precision-medicine heart company he led to a $13.1 billion acquisition by Bristol Myers Squibb in 2020. At Kardigan, he is applying the same playbook: marrying real-world clinical data, AI tools, and deep cardiovascular biology to deliver personalized medicines for heart disease — a field he believes is where oncology was 20 years ago. With $554 million raised and three late-stage clinical programs underway, Gianakakos is on a mission to make cardiovascular disease preventable and curable.